Alkylating agents induced secondary malignancies -A review (original) (raw)
Alkylating agents and cancer therapy
Jatinder Kaur
2007
View PDFchevron_right
Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents
Bipin Mehta
Cancer research, 1985
View PDFchevron_right
Preclinical studies and clinical correlation of the effect of alkylating dose
Beverly Teicher
Cancer research, 1988
View PDFchevron_right
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine
Gulshan Ara
Cancer Chemotherapy and Pharmacology, 1993
View PDFchevron_right
Major Differences between Tumor and Normal Human Cell Fates after Exposure to Chemotherapeutic Monofunctional Alkylator
Andy Tuck, Kandace Williams
View PDFchevron_right
Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor
Nabil Hajji
Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 2005
View PDFchevron_right
Translocation Mechanism in Secondary Leukemias Following Topoisomerase II Poisons
Naiyu Zheng
Hematology Meeting Reports, 2009
View PDFchevron_right
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
Boe Sorensen
Lung Cancer, 1991
View PDFchevron_right
Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo
Beverly Teicher
Cancer research, 1989
View PDFchevron_right
Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines
Beverly Teicher
Cancer research, 1986
View PDFchevron_right
Mutagenicity and carcinogenicity of topoisomerase-interactive agents
Nathan Berger
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 1994
View PDFchevron_right
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts
Maurizio D'Incalci
European Journal of Cancer, 1998
View PDFchevron_right
The effects of bifunctional alkylating anti-tumor agents on oncogene structure and function in the human tumor cell line Colo 3320 HSR
Bernard Futscher
View PDFchevron_right
Utilization of in vivo alkylated metabolites as a possible cause of increased sensitivity of tumor cells to alkylating agents
Michael Lerman
Molecular Biology Reports, 1975
View PDFchevron_right
Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines
Fauzia Khan
Journal of environmental biology / Academy of Environmental Biology, India, 2009
View PDFchevron_right
Carcinogenicity of the Anticancer Topoisomerase Inhibitor, Amsacrine, in Wistar Rats
Mohd Isneini
Toxicological Sciences, 1996
View PDFchevron_right
Topoisomerase II level and drug sensitivity in adult acute myelogenous leukemia
Erasmus Schneider
Blood
View PDFchevron_right
Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
John P Murnane
British Journal of Cancer, 1981
View PDFchevron_right
Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines
David Peereboom
JNCI Journal of the National Cancer Institute, 1996
View PDFchevron_right
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II
Erasmus Schneider
European Journal of Cancer and Clinical Oncology, 1988
View PDFchevron_right
Topoisomerase IIα expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C
Malin Prenkert
Oncology Reports, 2009
View PDFchevron_right
Effect of alkylating antitumor agents on the binding of DNA to protein
Jörg Schnierda
1973
View PDFchevron_right
Cancer Chemotherapy: A Review Update of the Mechanisms of Actions, Prospects, and Associated Problems
Eustace B.Berinyuy
2021
View PDFchevron_right
Combination of Bifunctional Alkylating Agent and Arsenic Trioxide Synergistically Suppresses the Growth of Drug-Resistant Tumor Cells 1,2
pei-chih lee
View PDFchevron_right
Enhancement of Antitumor Activity of Alkylating Agents by the Radiation Sensitizer Misonidazole
Raphael Catane
Cancer Research, 1980
View PDFchevron_right
Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient
George Ogata
Cancer research, 1994
View PDFchevron_right
The Effects of Arolycoricidine and Narciprimine on Tumor Cell Killing and Topoisomerase Activity
BUKET BOZKURT
Records of Natural Products
View PDFchevron_right
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells
kurt kohn
Cancer research, 1987
View PDFchevron_right
Epstein RJ, Smith PJEstrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res 48: 297-303
Paul Smith
Cancer Research
View PDFchevron_right
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy
Tauseef Ahmed
Leukemia, 2001
View PDFchevron_right
Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action
C. Pérez, Nuria Vilaboa
Journal of cell …, 1997
View PDFchevron_right
The incidence of secondary leukemias
Giuseppe Leone
View PDFchevron_right